ºÚÁϳԹÏÍø

Advocates for the LGBTQ+ community claimed a win this week after the Trump administration pledged to reinstate the 988 Suicide and Crisis Lifeline specialized support program tailored to their needs. During a Senate hearing earlier this week, HHS Secretary Robert F. Kennedy Jr. was asked whether he would commit to restoring the tailored line for LGBTQ+ callers to 988, as required by law, after the Trump administration removed it last summer. "We are working on getting it up now," Kennedy said. (Firth, 4/24)

The Texas Supreme Court tossed temporary injunctions Friday that halted child abuse investigations against parents who allowed their transgender kids to access puberty blockers and hormone therapy, in large part because the state has closed such inquiries into three families who sued and a fourth child is now an adult. (Langford, 4/24)

The Food and Drug Administration (FDA) announced on Friday It's issuing national priority vouchers to three companies to help fast-track the review of certain psychedelic medications. The companies are studying psilocybin for treatment-resistant depression and major depressive disorder and methylone for post-traumatic stress disorder (PTSD). These vouchers mean the FDA has 60 days to review the medications for approval. (Kekatos, 4/24)

This survey is one of the few to track psilocybin use in the previous 12 months, rather than just lifetime use. The study found that 2.8% of the U.S. population — about 8 million people — had used psilocybin during the study period. (Neff, 4/24)